Alpex Pharma SA
http://www.alpex.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alpex Pharma SA
PTO Affirms Shire’s Lialda Patent; First Decision In Kyle Bass IPR Case
Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.
Deals Shaping the Medical Industry (10/06)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
-
Drug Delivery
- Controlled Release
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice